$Biohaven(BHVN)$ 一月份的jpm会议上还有一些比较关键的数据展示 clinical data for two of its extracellular degrader programs from initial patient experience in the Phase 1b expansion cohorts BHV-1400 for IgAN and BHV-1300 for Graves' disease;expectations for the company's recently initiated Phase 2b study with taldefgrobep alfa in obesityoncology clinical stage assets;and emerging data from its ongoing clinical trial with BHV-7000 in adult focal epilepsy